By Adriano Marchese
Neuronetics shares jumped in premarket trading Tuesday after the company said it expects revenue to double from 2024 levels, rising above analyst expectations.
Shares traded 15% higher at $4.89.
For the full-year 2025, the medical device company expects total worldwide revenue to be between $145 million and $155 million. This is up from $74.9 million in 2024, and higher than the $93.5 million forecasted by analysts, according to FactSet.
Gross margins are projected to be 55%, while operating expenses are expected to fall within the range of $90 million to $98 million.
More immediately, in the first quarter, Neuronetics expects total revenue between $28 million and $30 million.
This is up from its latest fourth-quarter results where it generated $22.5 million in revenue, up from $20.3 million, beating analyst projections of a slight decline to $19.6 million and its own guidance range of between $19 million and $20 million.
Net loss in the quarter widened to $12.2 million from $5.4 million, which on a oer-share basis was a loss of 33 cents compared with a loss of 19 cents.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 04, 2025 08:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。